Pharmacy Regulatory Updates 06/21/2026
Federal Pharmacy Intelligence – June 20, 2026
Coverage window: Saturday, June 13 – Saturday, June 20, 2026
A day delayed, but here nonetheless.
Executive Layer
The Lilly binary event resolved against hospitals: AHA confirmed June 18 that Lilly is now actively denying 340B discounts to noncompliant holdouts, and Lilly simultaneously sued HRSA to force approval of its Kalderos-powered "cash replenishment" rebate model – so the data fight and the rebate fight are now converging in court. AHA confirmed that Eli Lilly has taken the extraordinary action of denying 340B discounts and called on Congress to demand HHS take a position.
HRSA's rebate-pilot ICR published June 15 and newly released supporting documents (June 18) show the agency moving quickly toward a 2027 pilot scoped to the IPAY 2026/2027 negotiated drugs – and a separate rebate proposed rule is still sitting at OMB – so the rebate model is advancing on two tracks, not dormant. The ICR is limited to manufacturers with Medicare Drug Price Negotiation agreements for IPAY 2026 and 2027; OMB may act only after the 30-day comment period closes, and OPA plans a separate Federal Register notice on criteria and standards – indicating HRSA may move ahead as soon as this summer.
Washington's SB 5981 produced its first real-world manufacturer behavior change – Novartis exempted Washington from its contract-pharmacy restrictions – even as PhRMA filed a third and AstraZeneca a fourth challenge to the law, and the 4th Circuit again sided with drugmakers by vacating the ruling that had upheld Maryland's law. Novartis exempted Washington from its contract-pharmacy restrictions while banning alternative distribution models; PhRMA filed a third lawsuit and AstraZeneca a fourth challenge to Washington's law; and the 4th Circuit vacated the ruling upholding Maryland's 340B contract-pharmacy access law.
340B is under intensifying political and structural pressure this week – a Senate HELP hearing featured witnesses critical of the program (one urging its replacement with a direct subsidy), RFK Jr. testified on the FY27 HHS budget, and the standing administration proposal to move 340B from HRSA to CMS remains live. A Senate committee witness called for replacing 340B with a direct subsidy program, and an upcoming Senate HELP drug-pricing hearing was set to include two witnesses critical of 340B.
The Section 232 pharma onshoring window (June 12) closed with no public applicant list and no new MFN deals; the next tripwire is July 31 (large-company effective), and FDA's new PreCheck domestic-manufacturing pilot (June 17) is an adjacent onshoring signal worth tracking.
Two FDA approvals: Tzield (teplizumab) gained a new pediatric Stage 3 type 1 diabetes indication (June 15 – an infused immunology biologic), and OTC naloxone access was broadened (June 16), which intersects the DEA MAT rule and your behavioral-health pharmacy workflows. FDA approved a new indication for Tzield (teplizumab) for certain pediatric patients with recently diagnosed Stage 3 type 1 diabetes on June 15 and broadened access to OTC naloxone nasal spray on June 16.
Section 1 – Federal Regulatory
FDA. An active approvals week, two items profile-relevant. FDA approved a new pediatric indication for Tzield (teplizumab) on June 15, broadened OTC naloxone nasal spray access June 16, approved the first single-dose generic influenza treatment June 17, and cleared the first OTC continuous glucose monitor for children June 12. Tzield is the one to flag operationally – it's a high-cost infused immunology biologic, so an indication expansion widens your infusion/specialty exposure (and its tariff status depends on patent/origin, see 1B). The naloxone OTC expansion dovetails with the DEA MAT rule (below) for behavioral-health and ED workflows. Separately and relevant to the tariff issue, FDA announced a PreCheck Pilot Program to strengthen domestic pharmaceutical manufacturing on June 17. That's an onshoring-incentive instrument running parallel to the Section 232 stick – worth watching as the carrot side of the same industrial-policy push.
CMS. No major drug-payment rule this week; the June 12 Drug Price Negotiation proposed rule (last week's item) is the active one. New this period: CMS published a June 15 notice opening comment on a comprehensive review of the Essential Health Benefits framework – tangential to acquisition economics, but a marker that the administration is reopening benefit-design questions broadly. The Section 1115 budget-neutrality guidance (implementing the 2025 reconciliation requirement) continues to constrain Medicaid demonstrations, including Indiana's.
DEA.No change this period. The material item remains last week's June 9 SUPPORT Act/MAT final rule (effective July 9) governing pharmacy delivery of MOUD to practitioners' registered locations – still the SOP trigger for your behavioral-health pharmacy services offered. Nothing new in the Federal Register Rules feed or Diversion Control this week.
HRSA. Two developments, both advancing the rebate model. First, the rebate ICR published June 15 as expected; OMB may act only after the 30-day comment closes, and a separate Federal Register notice will set criteria and standards, with the pilot limited to the IPAY 2026/2027 negotiated-drug manufacturers. Second, and new: on June 18, 340B Report reported that newly released HRSA supporting documents show the agency moving quickly toward another 340B rebate pilot in 2027. Note the two-track structure – the ICR (data collection) is distinct from the rebate proposed rule, which remains at OMB for review. Meanwhile HRSA remains publicly silent on the manufacturer data policies even as Lilly executes its cutoff and AHA renews its demand for enforcement – the silence is, again, itself the story.
Courts. The week's most consequential filing: Lilly sued HRSA over its rejection of Lilly's "cash replenishment" model – operated through technology partner Kalderos – which would pay covered entities cash weekly at no more than the 340B ceiling price; Lilly argues HRSA lacked authority to reject it. This matters enormously because if Lilly (or J&J, on a parallel track) wins judicial blessing for a manufacturer rebate model, it undercuts the legal premise protecting up-front 340B discounts – the same structural threat the HRSA pilot poses, but pursued through litigation. On the contract-pharmacy front, the 4th Circuit again sided with drugmakers and vacated the ruling upholding Maryland's law, while PhRMA and AstraZeneca filed the third and fourth challenges to Washington's SB 5981. The 1st Circuit (Maine/Rhode Island, argued June 4) and the 4th Circuit en banc (West Virginia/Maryland) remain pending.
Section 1B – Trade & Tariff Policy (Pharmaceutical)
Quiet again – a deadline passed, no new substance. Not trimmed; short by the delta rule.
Onshoring window / BIS. The June 12 application deadline is now eight days past with no public outcome – applications are confidential and no applicant list, approved agreement, or Annex III addition has been announced. The structure is firmly confirmed: the 100% tariff takes effect July 31, 2026 for the 17 Annex III (large) companies and September 29, 2026 for all others. The relief tiers: an approved onshoring agreement yields a 20% rate from September 29, 2026 through April 2, 2030, and onshoring plus an MFN agreement yields 0% from July 31, 2026 through January 20, 2029. Next trigger: July 31, the first real invoice event.
Generic / biosimilar extension.No change. Section 232 tariffs still do not apply to generic pharmaceutical products and associated ingredients. Advisory due by April 2, 2027.
MFN / CMMI.No new MFN signing this period. No new GLOBE/GUARD clarification. The adjacent development is FDA's June 17 PreCheck domestic-manufacturing pilot (Section 1) – the onshoring carrot to the tariff stick.
Adjacent 232 tracks (devices, PPE, robotics).No change. September 2025 investigations still open, no determination – the standing tripwire for the infusion-pump and disposables supply chain.
Litigation.No change. No suit challenging the pharma tariffs; the metals 232 track (amended again June 1, effective June 8) reaffirms that this administration tightens and re-tweaks 232 regimes rather than delaying them – a useful precedent that the pharma July 31 / September 29 dates are more likely to hold than slip.
Read-through (unchanged): retail and biosimilar lines carved out; patented Part B infusion and specialty exposed at 100%, reducible to 20%/0% by company agreement; country rates 15% (EU/Japan/Korea/Switzerland/Liechtenstein), 10% (UK). Newly approved June 15 Tzield falls in the exposed patented-biologic bucket unless its manufacturer secures relief. Nothing bills until July 31.
Section 2 – State Regulatory (Indiana and Ohio)
Indiana.No new state action this week, but the clock is the story: the Medicaid 340B reimbursement cutoff remains set for July 1, now ~11 days out, and Indiana hospitals are not covered by the FQHC exemption – so PRMC loses 340B value on Indiana Medicaid managed-care claims in under two weeks. The May 28 IHCP bulletins (BT202685 Medicare-eligible exclusion effective Oct 1; BT202684 DUR Board effective Aug 1) remain as previously briefed.
Ohio.Nothing material this week. H.B. 229 PBM licensure remains effective July 1, 2027.
National-trend read. The state wave kept moving: Novartis exempted Washington from its contract-pharmacy restrictions in response to SB 5981 – the first concrete instance of a state access law forcing a manufacturer to stand down – even as the litigation against that law multiplied. Oregon sent a 340B contract-pharmacy access bill to its governor, and Illinois fell short on a 340B access bill but advanced PBM reform. The two-front dynamic (states shielding access, manufacturers litigating and imposing data mandates) is intensifying, and Washington is the live test case.
FDA authorizes Colorado's Canadian drug importation program (June 15). FDA approved Colorado's Section 804 program — the second state authorization after Florida — covering ~20 drugs (Biktarvy, Eliquis, Erleada, others), projected to save $46M over three years, with a two-year authorization and a pre-import-request process. Targets the commercial insured population only (Medicaid/Medicare excluded, as 340B/Medicaid pricing already beats import prices). Limited direct impact for a 340B DSH hospital, and uncertain even in-state given manufacturer non-participation and Canada's bulk-export safeguards (Florida has imported nothing despite approval). Two angles to watch: (1) a policy collision with Section 232 — Canada is not a preferential-rate country, so patented imports could face the 100% pharma tariff absent a carve-out, undercutting the savings; (2) a national-trend precedent that hospital pharmacy groups oppose, with ~7 more states in the queue.
Section 3 – Payer Policy Updates
Nothing material verified this week across Anthem (IN/OH), UnitedHealthcare, Humana, Aetna, CareSource, or Medical Mutual of Ohio. The consequential UHC oncology cluster – June 1 chemo PA via Optum's Cancer Guidance Program, the Aug 1 site-of-care expansion, the Sept 1 injectable-oncology exclusions – was last week's news and is now in execution; no new bulletin-level change surfaced June 13–20.
Section 4 – Industry Intelligence
Manufacturer data policies – Lilly moves from threat to execution. The operational story is that Lilly actually pulled the trigger: Lilly reported ~70% compliance (about 2,350 entities) and roughly 1,000 holdouts; of the 50 largest holdouts it contacted, 11 did not respond and 13 met without reaching any commitment, and an initial set of holdouts has now been notified that wholesalers will pull their 340B pricing eligibility. The count of manufacturers with in-house data policies stands at nine, with exemptions for covered entities in states that have 340B-related laws (Washington's exemption from Novartis is exactly that mechanism in action).
The strategic point is : the wholesaler-cutoff enforcement model is now proven operationally, the manufacturer set is widening, and the only thing blunting it is state law – which makes Indiana's lack of a contract-pharmacy access statute a real vulnerability relative to Washington-sited peers.
The Kalderos angle. Lilly's "cash replenishment" lawsuit names Kalderos as its technology partner; Kalderos has been publicly arguing that claims-level transparency must be the foundation of 340B reform (its Truzo product). That tells you the rebate-model fight has a maturing vendor/infrastructure layer behind it – this isn't a one-off legal gambit.
Structural – the HRSA→CMS migration. Worth elevating to a watch item: the administration's FY27 budget request would shift the 340B program from HRSA to CMS while maintaining current OPA funding, and stakeholders are offering mixed views. A CMS-run 340B would sit inside the same apparatus running drug-price negotiation and the MFP machinery – structurally less hospital-friendly and more aligned with the rebate/duplicate-discount agenda.
Drug shortages and M&A.Nothing newly material this week with oncology/infusion impact; the chronic sterile-injectable vulnerability and the India cisplatin/carboplatin price-cap signal (from ~June 11) remain the standing watch. No new pharmacy-supply-chain M&A.
Section 5 – Closing: Three Things to Watch
1. Regulatory deadlines and court dates in the next 30 days.July 1 – Indiana's Medicaid 340B cutoff for hospitals and the GLP-1 Bridge go-live, same day. July 9 – the DEA SUPPORT Act/MAT final rule takes effect. ~July 15 – the rebate-pilot ICR comment period closes (OMB can't act before then). July 24 – Section 122 global tariff expires. July 31 – Section 232 large-company/Annex III tariffs effective, the first real pharmaceutical-tariff invoice event. Active litigation to track: Lilly v. HRSA (cash replenishment), the 9th Circuit (Washington appeal), the 1st Circuit (Maine/Rhode Island), and the 4th Circuit en banc.
2. Manufacturer or payer moves that may break in the coming week. Whether a 10th/11th manufacturer follows Lilly into actual execution now that the wholesaler-cutoff model is proven; whether HRSA finally responds to the AHA's renewed enforcement demand (still silent); and HRSA's separate Federal Register notice setting the rebate pilot's criteria and standards, which the agency has signaled could come "as soon as this summer." Watch also for more Washington exemptions or challenges as SB 5981 beds in.
3. Structurally likely, but not yet news. Two convergences. First, the Lilly cash-replenishment lawsuit is the sleeper – if a court rules HRSA lacks authority to reject manufacturer rebate models, that judicial holding could do what the enjoined HRSA pilot couldn't: legitimize the shift from up-front discounts to manufacturer-controlled rebates across the whole program. That's the single largest structural threat to the 340B cash flow, and it's now live in court rather than hypothetical. Second, the HRSA→CMS migration in the FY27 budget, converging with the rebate ICR and the data-policy enforcement, points toward a 340B program administered inside the drug-price-negotiation apparatus – a materially less favorable home for a DSH covered entity. Neither is a headline yet; both are where the program is heading.
